Drug profile · INN
certolizumab pegol
CIMZIA
certolizumab pegol (CIMZIA) is a tnf-alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — certolizumab pegol
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
certolizumab pegol (CIMZIA) is a tnf-alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
TNF-alpha inhibitor
Primary target: Tumor necrosis factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is certolizumab pegol?
certolizumab pegol (CIMZIA) is a tnf-alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for certolizumab pegol?
CIMZIA is a marketed brand name for certolizumab pegol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of certolizumab pegol?
certolizumab pegol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.